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Review

Vaccine development against tuberculosis (TB) is based on the induction of adaptive
immune responses endowed with long-term memory against mycobacterial antigens.
Memory B and T cells initiate a rapid and robust immune response upon encounter with
Mycobacterium tuberculosis, thus achieving long-lasting protection against infection.
Recent studies have shown, however, that innate immune cell populations such as myeloid
cells and NK cells also undergo functional adaptation after infection or vaccination, a de
facto innate immune memory that is also termed trained immunity. Experimental and
epidemiological data have shown that induction of trained immunity contributes to the
beneficial heterologous effects of vaccines such as bacille Calmette-Guérin (BCG), the
licensed TB vaccine. Moreover, increasing evidence argues that trained immunity also
contributes to the anti-TB effects of BCG vaccination. An interaction among immunological
signals, metabolic rewiring, and epigenetic reprogramming underlies the molecular
mechanisms mediating trained immunity in myeloid cells and their bone marrow
progenitors. Future studies are warranted to explore the untapped potential of trained
immunity to develop a future generation of TB vaccines that would combine innate and
adaptive immune memory induction.
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Vaccine development against tuberculosis (TB) is based on the induction of adaptive immune responses endowed with
long-term memory against mycobacterial antigens. Memory B and T cells initiate a rapid and robust immune response upon
encounter with Mycobacterium tuberculosis, thus achieving long-lasting protection against infection. Recent studies have
shown, however, that innate immune cell populations such as myeloid cells and NK cells also undergo functional adaptation
after infection or vaccination, a de facto innate immune memory that is also termed trained immunity. Experimental and
epidemiological data have shown that induction of trained immunity contributes to the beneficial heterologous effects of
vaccines such as bacille Calmette-Guérin (BCG), the licensed TB vaccine. Moreover, increasing evidence argues that trained
immunity also contributes to the anti-TB effects of BCG vaccination. An interaction among immunological signals, metabolic
rewiring, and epigenetic reprogramming underlies the molecular mechanisms mediating trained immunity in myeloid cells
and their bone marrow progenitors. Future studies are warranted to explore the untapped potential of trained immunity to
develop a future generation of TB vaccines that would combine innate and adaptive immune memory induction.

Introduction

Vaccination has made an enormous contribution to improving
human and animal health over the last two centuries (1–6). Despite
progress in developing vaccines against a large number of infections,
vaccine development against global chronic infectious disease threats
such as tuberculosis (TB), HIV infection, and malaria has remained a
challenge, and achievements to date have been modest.
TB kills more than 1.3 million people a year (7). The current
vaccine, bacille Calmette-Guérin (BCG), is an attenuated strain of
Mycobacterium bovis and has been in use since the 1920s; approximately 100 million infants receive BCG annually. BCG is efficient
in children, with greater than 50% protection against lung disease
and more than 80% protection against disseminated forms of TB (8).
Importantly, however, children do not spread TB, while adolescents
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and adults do (9). Unfortunately, BCG has shown variable and mostly
poor protection against TB in adolescents and adults. Therefore, new
vaccines that target both children and adult populations are needed.
Multiple TB vaccine candidates have entered clinical trials.
In 2018, two major clinical advances were reported. The novel
subunit vaccine M72/AS01E was shown to prevent progression to
pulmonary TB disease in adults with prior immunological sensitization to Mycobacterium tuberculosis (Mtb), measured by Quanti
FERON-TB (QFT; QIAGEN), with an efficacy of 54% (95% CI,
3%–78%) (10). In a second trial, BCG revaccination in adolescence
was shown to protect QFT-negative adolescents against sustained
QFT conversion, indicative of established Mtb infection, with
an efficacy of 45% (95% CI, 6%–68%) (5). These results require
confirmation but provide early proof of principle that adolescent/
adult TB vaccination strategies may be feasible. In the preclinical
space, a CMV-vectored vaccine has shown the best protection
reported to date against Mtb challenge in nonhuman primates and
is on track to enter clinical trials (11).
Despite this progress, new TB vaccine discovery and develop
ment remain impeded by our limited understanding of host re

REVIEW

The Journal of Clinical Investigation  

Figure 1. Sequential activation of innate and adaptive immunity during infection, and activation of a long-term memory response through T and B lymphocytes. The life cycle of memory T cells is depicted in corresponding phases of pathogen infection, clearance, and memory response. In secondary lymphoid
organs (e.g., lymph node [LN]), APCs process and present microbial antigen to naive T (TN) cells and convert them to effector T (Teff) cells. These Teff cells
then migrate to infected peripheral tissues (e.g., lung) to control infection. After pathogen clearance, Teff cells substantially contract, but a small fraction of
antigen-experienced Teff cells convert to: effector memory T (Mem Teff) cells, circulating between lymphoid organs and peripheral tissues; tissue-resident
memory T (Mem TTR) cells, residing in peripheral tissues; and central memory T (Mem TC) cells, which are long-lived and reside in secondary lymphoid organs.

sponses required to control Mtb, as well as technical gaps such as
animal models that are predictive of human immune responses
(3). Whereas traditional approaches to TB vaccine development
have focused on optimal engagement of the adaptive immune
system, mainly due to the memory capacity of T cells, according
to an emerging paradigm the innate immune system has memorylike capacity (termed trained immunity) (2, 6) and plays a role in
the “nonspecific” beneficial effects of vaccines. In this Review, we
explore the rationale for targeting the innate immune mechanisms
for improving vaccines against TB.

Classical design of vaccines: targeting adaptive
immunity

Classical design of vaccines is based on priming of antigenspecific naive B and T cells to generate memory B and T cells,
which are able to initiate a rapid and robust immune response
upon encounter with the same pathogen, thus achieving longlasting protection from initial infection or disease (Figure 1).
B and T cell specificity is dependent on somatic rearrangement
of genes coding for receptors that recognize specific epitopes and
can distinguish self and non-self (12). When naive lymphocytes
are presented with their cognate antigen in the appropriate cytokine milieu, they become activated and undergo clonal expansion,
thereby exponentially increasing the magnitude of antigen-specific
cells over several days. During priming, B and T cell transcriptional
profiles are epigenetically modulated and drive differentiation
into effector and memory cells (13) (Figure 1). Activated B cells
undergo immunoglobulin class switching and somatic hyper
mutation to produce high-affinity Abs with diverse effector functions. Activated T cells rapidly produce effector molecules, such as
cytokines and cytotoxic mediators (14), and experience metabolic
reprogramming (15). Activation-induced changes in gene expres-

sion also affect expression of surface molecules that mediate homing to lymphoid and peripheral tissues, where pathogens are most
likely to be encountered. Effector T cells migrate to the infected
tissues to control infection, then contract, leaving a smaller pool of
long-lived memory cells, mostly residing in the bone marrow (BM)
or lymphoid tissues. If they encounter the same pathogen again,
antigen-specific memory cells react faster and more efficiently
than during primary infection. Less differentiated T cells, such
as memory stem cells (16) and central memory cells (17), retain
high proliferative capacity, associated with long-term anamnestic
responses after vaccination (18). More differentiated T cells, such
as circulating effector (17) and tissue-resident memory T cells (19),
exhibit strong effector functions that are important for immediate
protection against pathogens (20) (Figure 1). A balanced induction
of T cells endowed with long-term memory as well as the capacity
to rapidly migrate to the lung parenchyma is important for T cell–
mediated protection against TB (21).
Antigen-presenting cells, amplification of the response through
costimulatory molecules, and T cell receptor signal strength play
key roles in shaping T and B cell differentiation and functional
polarization during priming (22, 23). Regardless, T cells maintain
both functional and differentiation plasticity, being able to switch
expression of lineage-regulating transcription factors (24) as well
as to dedifferentiate (25). Vaccine formulation and delivery shape
the distinctive features of adaptive immune responses, and antigen selection determines the specificity and breadth of vaccineinduced immune responses. Highly expressed immunodominant
antigens are commonly included in vaccines, but antigen selection has not been straightforward for TB vaccines. Mtb contains
approximately 4000 genes (26), many of which are expressed
differentially during infection (27). T cell epitopes are conserved
in Mtb (28), suggesting an evolutionary advantage of T cell recogjci.org   Volume 129   Number 9   September 2019
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nition, possibly to drive lung tissue damage and TB transmission,
but T cell recognition could also contribute to protection, since most
individuals do not develop TB following exposure. Indeed, decoy
mechanisms such as export of mycobacterial antigens from infected
cells (29) divert T cell recognition to promote bacterial persistence.
The development of MTBVAC, a live attenuated vaccine retaining most antigens present in virulent Mtb, therefore, represents a
radical approach to circumvent biased antigen selection (30).
The functional attributes of protective T cells are not fully
understood. Several lines of evidence in humans and animal models point toward a protective role for Th1 and Th17 cells (21). A direct
comparison of six candidate TB vaccines in clinical testing showed
remarkable similarities in the Th1 functional profiles of vaccineinduced CD4+ T cells, with M72/AS01E inducing the highest
magnitude of memory responses (31). Whether such potent T
cell responses are associated with the partial protection against
TB afforded by M72/AS01E (10) will be established in correlates
of protection studies. On the other hand, accumulating evidence
indicates that unleashing T cell responses via reprogramming T
cell metabolism (32) or checkpoint inhibitors (e.g., programmed
cell death 1 [PD-1]) (33, 34) increases susceptibility to TB.
The role of B cells in mediating TB vaccine efficacy is emerging but incompletely understood. Animal models and human TB
provide clear evidence that proliferating antigen-specific B cells
localize within protective granulomas, highly specialized spatial
structures that develop for the containment of infection (35).
More recent evidence suggests that Abs from latently infected
individuals drive enhanced phagolysosomal maturation, inflammasome activation, and macro
phage killing of intracellular
Mtb when compared with Abs isolated from TB patients (36).
These differences in functional outcomes have been linked to
the Fc functional profiles of the Abs, selective binding to the
Fcγ receptor FcγRIII, and distinct Ab glycosylation patterns
found in Abs from healthy persons with Mtb infection compared with TB patients. Also, while Mtb-exposed individuals
and patients with TB generate Ab responses against mycobacterial surface antigens and are protective against cell invasion,
the inhibitory activity of anti-Mtb Abs appears to be limited to
the IgA isotype (37). Recently, individuals highly exposed to
Mtb who tested negative by QFT and tuberculin skin test (TST)
were considered “resisters” and shown to possess IgM, classswitched IgG Ab responses, and non–IFN-γ T cell responses
to Mtb-specific proteins (38). In TB, localization of CXCR5expressing CD4+ T cells within B cell follicles in TB granulomas
near Mtb-infected macrophages mediates superior Mtb control
(35, 39). Thus, it is possible that in addition to T cells, B cells
also engage and participate in effective generation of vaccineinduced immunity against TB.

Vaccine choice and delivery impact immune
responses

Vaccine formulation (e.g., choice of adjuvants and live attenuated vectors) can affect the magnitude and functional quality of
vaccine-induced adaptive immune responses (40); therefore,
knowledge about appropriate responses to a pathogen is essential
for rational vaccine design. Adjuvants and live vectors provide a
danger signal for a large variety of innate immune cells, such as
3484
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neutrophils, macrophages, monocytes, and DCs. In the traditional setting, adjuvants initiate priming and expansion of naive
T cell responses through DC activation that leads to DC maturation and migration to the draining lymph node, where they prime
naive B and T cells. Depending on the pattern recognition receptor (PRR) activated on DCs, different costimulatory and cytokine
milieus are induced, thus affecting differentiation and polarization of adaptive immunity (41, 42). However, by broadly activating diverse innate immune cell types, adjuvants can also alter the
activation state and epigenetic reprogramming of innate immune
cells, including those potentially exposed to Mtb.
In addition to adjuvants, the choice of vaccine delivery (such
as route and schedule of immunizations) can influence tissue
localization and longevity of vaccine-induced immune responses
(43, 44). This appears particularly important in TB, where T
cells homing to the lung parenchyma are associated with superior protection compared with those that remain intravascular
in a mouse model (45, 46). Intravenous or lung mucosal BCG
administration is associated with reduced TB pathology compared with intradermal vaccination in nonhuman primates (47,
48). Mucosal vaccination with an attenuated Mtb vaccine candidate, Mtb sigH, induces B cell–harboring lymphoid follicles in
the lung that serve as local immune structures to mediate highly
effective T cell immune responses and better protection than
even mucosal BCG vaccination (39). Live BCG can also induce a
specific cytokine profile in human APCs to promote T follicular
helper (TFH) cell differentiation (49).
Another TB vaccine candidate based on a recombinant CMV
vector (RhCMV/TB) conferred complete protection in approximately 40% of nonhuman primates (11). Although this vaccine,
administered subcutaneously, induced and maintained highly
differentiated circulating and tissue-resident memory T cells,
protection was associated with innate cell (particularly neutrophil) activation (11). Furthermore, as discussed further below,
targeting innate immune activation pathways, specifically CD40/
CD40L and CD103+ DCs in mouse models, can induce rapid
antigen-specific T cell responses, formation of B cell lymphoid
follicles, and superior near-sterilizing immunity in the lungs of
BCG-vaccinated mice (50). These studies together provide new
avenues to target innate immune responses to improve T and B
cell responses for TB vaccines. Ultimately, adaptive and innate
immune responses work in a coordinated fashion during both
priming and effector phases of a successful immune response.

Available adjuvants and their functions

Innate immunity plays a key role in TB vaccine responses through
an increase in the function of antigen-presenting cells by vaccine
adjuvants. Although some types of vaccines, such as live attenuated (e.g., yellow fever), whole cell (e.g., BCG), and certain killed
vaccines (e.g., inactivated polio vaccine [IPV]), do not need specialized adjuvants as part of the vaccine formulation, most if not
all subunit/protein vaccines require adjuvants to trigger innate
immune activation for efficient humoral and/or T cell responses
for effective vaccine efficacy (51). Few adjuvants are licensed for
use in humans, including the aluminum-containing adjuvants
CPG 1018, MF59, and AS01, but recently, there has been progress
in advancing more formulations for clinical use.
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Adjuvants are categorized based on composition, delivery systems, and their ability to trigger innate immune activation (52).
Aluminum-containing adjuvants (e.g., alum) have been used for
more than 70 years and are suggested to stimulate the inflamma
some (53), but their mode of action is still not fully characterized.
Oil-in-water emulsions such as MF59 and AS03 attract neutrophils and traffic antigen to lymph nodes (54). TLR4 agonists mimic specific danger signals (e.g., bacterial LPS, microbial DNA, or
single- or double-stranded RNA) that trigger surface or intracellular receptors to induce innate pathways in antigen-presenting
cells to program adaptive immunity. The plant-derived saponin
QS21 elicits the release of alarmins, which activate DCs and the
inflammasome to generate CD8+ T cell responses and IgG1 and
IgG3 Ab production (51, 55). Thus, one key commonality of many
adjuvants is the stimulation of IL-1 cytokine family members (56).
The mechanisms associated with the performance of licensed
adjuvanted vaccines is the subject of a recent review (57).
There are several experimental adjuvanted subunit TB vaccines in clinical testing (see Global Clinical Portfolio of TB Vaccine Candidates, http://www.aeras.org/pages/global-portfolio).
The M72/AS01E vaccine formulation, which was recently reported
to have efficacy against pulmonary TB, contains the combination
adjuvant AS01, which is part of the successful commercial vaccine Shingrix (GSK) and a recombinant fusion protein antigen
(10). AS01 is composed of QS21, liposomes, and the TLR4 agonist
monophosphoryl lipid A (MPL; a detoxified derivative of bacterial
lipopolysaccharide). The proposed mechanism of action of the
adjuvant involves triggering naturally occurring innate immune
pathways including early release of alarmins by innate immune
cells and IFN-γ by NK cells (58, 59).
The adjuvant glucopyranosyl lipid adjuvant (GLA) is a synthetic lipid A molecule and TLR4 agonist formulated into a stable
oil-in-water nanoemulsion (SE) that drives Th1 immune responses
(55). GLA-SE is part of an experimental TB vaccine formulation
with fusion of four Mtb protein antigens called ID93 (60). Firstin-human studies of ID93 showed improved Ab and CD4+ T
cell responses in GLA-SE–adjuvanted versus unadjuvanted vaccine (61). The vaccine was safe and immunogenic in previously
BCG-vaccinated adults (62). A phase IIa clinical trial in treated TB
patients (NCT02465216) has completed, and a lyophilized formulation has entered phase I (NCT03722472).
In addition, two cationic particulate adjuvants, IC31 (Valneva
Technologies) and CAF01 (Statens Serum Institut), are being
tested among experimental TB vaccines. A vaccine comprising the
H56 fusion protein formulated with IC31 has completed phase I
testing (63, 64) and is being evaluated in a phase II clinical trial
for preventing TB recurrence (NCT03512249). A different IC31adjvuanted subunit vaccine, H4:IC31, was evaluated for prevention of Mtb infection (5). Adjuvant formulation is also important, as shown for the novel TB vaccine candidate M72/AS01E.
Adjuvants AS01 and AS02 contain the same components (MPL
and QS21) formulated in either liposomes (AS01) or oil-in-water
emulsion (AS02). While both formulations generated potent
and durable Ab responses, AS01 induced a higher magnitude of
antigen-specific Th1 responses (65). Thus, the choice of adjuvant
for a vaccine candidate should depend on properties tailored to
the specific vaccine Target Product Profile (TPP).

Interpretation of trained immunity as innate
immune memory

In addition to the classical role of innate immunity in amplifying
T/B cell immune memory through adjuvant activity, recent studies provide evidence that a prolonged increase in the antimicrobial function of innate immune cells can itself contribute to protection from reinfection. This functional reprogramming of innate
immune cells such as myeloid and NK cells, termed trained immunity, represents a de facto innate immune memory (6). Trained
monocytes and macrophages display functional and epigenetic
reprogramming, leading to increased production of cytokines and
chemokines, and improved phagocytosis and killing capacity (66).
Studies have demonstrated that immunological signals, metabolic
rewiring of cell metabolism, and epigenetic reprogramming are
integrated, representing the molecular substrates for induction
of trained immunity (6). The first step involves immunological
signals induced through PRRs such as dectin-1 (in the case of
β-glucans) and NOD2 (for BCG). The molecular link between
these signals and the epigenetic changes in the nucleus has
recently been attributed to changes in cellular metabolism. An
initial study reported that induction of trained immunity is accompanied by a shift from oxidative phosphorylation to glycolysis, or
the Warburg effect (67). Subsequent studies have shown that the
Krebs cycle is replenished through glutaminolysis, leading to
accumulation of succinate and especially fumarate. In turn, fumarate inhibits the KDM5 family of demethylases, which are specific
for H3K4me3; this inhibition permits the retention of this active
histone mark (68). Induction of trained immunity leads to an
increase in the mevalonate pathway; mevalonate in turn amplifies
this process through an insulin-like growth factor 1 (IGF-1R)/Akt/
mTOR pathway (69) (Figure 2).
The changes described above have an important impact
on the epigenetic program of trained myeloid cells. The beststudied epigenetic changes to immune stimuli involve the posttranslational modification of histone tails at promoter and
enhancer regions (70, 71). In response to training signals, histone
acetylation and methylation play an important role in regulation
of gene expression and remodeling of the epigenome, which
are important molecular mechanisms implicated in modulating
innate immune cell signaling (6). Prior to gene expression, the
promoters of innate immune genes are “preloaded” with poised
RNA polymerase II, and neighboring histones possess active
histone marks such as H3K4me3 (72, 73). A rise in the level of this
active mark, as well as other active marks such as H3K4me1 and
H3K27Ac, is a hallmark of trained immunity (74). Indeed, training with β-glucan leads to H3K4me3 accumulation at specific
locations in the genome (74). H3K4me3 is directed to specific
promoters in the genome by the presence of a class of long noncoding RNAs (lncRNAs) called immune gene–proximal lncRNAs
(IPLs) (75). IPLs are positioned within topological associating
domains (TADs), regions of enriched chromatin long-range looping interactions bringing together multigene complexes (76).
Within TADs, IPLs recruit a histone modification complex, the
COMPASS complex, which in turn directs the trimethylation of
H3K4me3 (75, 77, 78). IPLs are transcribed in an nuclear factor of
activated T cells–dependent (NFAT-dependent) manner. Silencing of IPLs, disruption of the COMPASS complex, or abrogation
jci.org   Volume 129   Number 9   September 2019
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these cells have a relatively short lifespan
and are less likely to transmit their memory
phenotype to their progeny and provide
sustainable protection. In contrast, hemato
poietic stem cells (HSCs) are long-lived,
with self-renewal properties that reside in
the BM, and their transcriptional and functional reprogramming can explain trained
immunity induction (Figure 3). In vertebrates, HSCs are generated from endothelial cells in the embryo, which depends on
type II IFN signaling (79). The BM is the seat
of hematopoiesis, where HSCs constantly
undergo asymmetric division, giving rise to
the full repertoire of myeloid and lymphoid
cell types while maintaining the HSC niche.
Importantly, HSCs can directly respond to
acute and chronic infections. For example,
in a model of acute Escherichia coli infection
(80) or chronic Mycobacterium avium infection (81), there was a significant expansion
in HSC populations. Similarly, trained
immunity induced by BCG vaccination (82)
or β-glucan (83) was recently shown to be
mediated through increased myelopoiesis
in the BM. Although the exact mechanisms
of precursor proliferation/differentiation
are not well understood, persistent activation of HSCs can result in BM exhaustion and even complete depletion of HSCs
over time, leading to devastating effects on
the systemic immune compartment (84–
86). Thus, the balance between HSC selfrenewal and differentiation must be tightly
regulated to maintain the numbers of HSCs
for the generation of trained immunity.
Recently, several mechanisms have
Figure 2. Molecular mechanisms contributing to the induction of trained immunity in myeloid cells. been proposed to explain HSC activation
Activation of myeloid cells by microbial β-glucan or BCG activates PRRs that in turn activate gene
(87) in the setting of infectious disease,
transcription, but also cellular metabolism through an Akt/mTOR-dependent pathway. Activation
including the following: (i) Direct infecof lncRNAs such as UMLILO determines chromatin changes by activation and transport of histone
tion: HSCs are thought to lack the molecmethyltransferases. Long-term metabolic changes such as fumarate accumulation maintain these
ular machinery required for phagocytosis.
changes by inhibiting KDM5 histone demethylases. In turn, mevalonate release amplifies these
changes through an IGF-1R–dependent loop. TCA, tricarboxylic acid.
Pathogens including Salmonella, Listeria,
Yersinia, M. avium, and BCG are unable
to infect HSCs (81, 82, 88), but Mtb infecof NFAT signaling results in loss of H3K4me3 accumulation at
tion can gain access to HSCs (89, 90). Recent data indicate that
trained immune genes (75). IPLs are generally conserved across
Mtb infects BM mesenchymal stem cells, which are phagocytic,
mammals at the sequence and syntenic level; however, a key IPL
and bacteria can survive within these cells (91, 92). (ii) PRR
regulating trained immunity of the chemokine locus is absent in
signaling: HSCs express both cell-surface TLRs (e.g., TLR4,
rodents, so CXCL1–3 cannot be trained in mice. Training in mice
which recognizes bacterial LPS) and cytosolic NOD-like recepcan be restored by inserting the human IPL (UMLILO) proximal
tors (e.g., NOD2, which recognizes bacterial MDP) that not
to the mouse chemokines via gene editing (75).
only play important roles in anti-Mtb immunity, but also drive
infection-induced myelopoiesis (generation of monocytes and
macrophages), cell mobilization from BM into infection site,
Trained immunity: the impact on myeloid cell
and trained immunity (93–96). (iii) Cytokine signaling: Quanprogenitors
titative changes in HSC activity are regulated by cytokines
Although trained immunity was first established in cells of the
relevant to TB. In vertebrates, both type I IFNs (IFN-α and -β)
mononuclear phagocyte lineage (i.e., monocytes and macrophages),
3486
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Figure 3. Induction of trained immunity in myeloid cells. Induction of trained immunity by vaccination leads to cellular reprogramming toward a myeloid
bias in the BM. Monocytes with rewired transcriptional and epigenetic programs differentiate into trained recruited lung macrophages with increase antimicrobial activity. CMP, common myeloid progenitor; GMP, granulocyte-monocyte progenitor; BMDM, BM-derived macrophage.

and type II IFN (IFN-γ) can increase HSC proliferation (81, 84,
86, 97), but they have opposing effects in the killing of Mtb by
macrophages (98, 99). Furthermore, increased activation of
HSCs following M. avium infection or the generation of HSCmediated trained immunity via BCG intravenous vaccination
was shown to be IFN-γ dependent, highlighting the pivotal role
of IFNs in HSC responses to mycobacterial infection (81, 82).
While basal levels of IFN signaling are required to maintain the
balance between HSC self-renewal and differentiation during
homeostasis, chronic exposure of HSCs to IFNs during chronic
infections may lead to BM aplasia (79). Interestingly, the role
of IFN-dependent pathways in regulating HSC responses and
downstream consequences following infection with virulent
strains of Mtb is still unknown. Although this study indicates that
type II IFN is required for generating trained immunity by HSCs
after BCG vaccination (82), another study showed that β-glucan–
induced trained immunity by HSCs was mediated via GM-CSF
and IL-1 signaling (83). These observations suggest that different
stimuli (e.g., live pathogen versus pathogen-derived products)
may imprint distinct molecular signatures in HSCs that each lead
to trained immunity.
The molecular mechanisms required for inducing trained
immunity in the BM require the same epigenetic rewiring events
described earlier for mature myeloid cells. It was recently demonstrated that BCG can reprogram HSCs toward myelopoiesis, leading to generation of protective monocytes/macrophages against
subsequent Mtb infection. Most importantly, this protective
signature was transmitted from HSCs to multipotent progenitors (MPPs) to monocytes and macrophages. Epigenetic analysis
of BCG-trained, BM-derived macrophages indicates that the
H3K4me3 and H3K27Ac marks are significantly enriched for
genes associated with resistance to Mtb infection. These results

provide a mechanism for how in vivo BCG vaccination epigenetically primes BM-derived macrophages to initiate a robust protective response against Mtb infection (82). These data are supported by studies describing similar mechanisms at the HSC level
induced by β-glucan (83).

Targeting NK memory for TB vaccines

NK cells are prominent components of the innate immune system
that play a central role in resistance to microbial pathogens. NK
cells protect against viruses, bacteria, and parasites by destroying
infected cells and secreting cytokines that shape the adaptive
immune response (100–103). NK cells contribute to immunity
against Mtb infection by lysing Mtb-infected human monocytes and
alveolar macrophages and upregulating CD8+ T cell responses (104,
105). The pleural fluid of TB patients is enriched for NK cells, which
are the predominant source of IFN-γ (106), and a subpopulation
expresses the memory-associated marker CD45RO, thus exerting robust immune responses when stimulated by IL-12 (107). NK
cells lyse Mtb-expanded Tregs (108), and eliminating NK cells at
the time of BCG vaccination enhances Treg expansion and inhibits
BCG-induced protection against challenge with Mtb (109). Accordingly, in mice, memory-like NK cells develop during BCG vaccination, expand, and provide protection against challenge with Mtb
(110). Recently, a multicohort study found higher numbers of cytotoxic NK cells in persons with latent TB than in uninfected individuals. These NK cells decreased during the progression from latent
infection to active disease and returned to the baseline level after
TB treatment, suggesting a protective role for NK cells during Mtb
infection (111). BCG revaccination of adults with latent TB infection
also induces long-lived BCG-reactive NK cell responses (112). Studies suggest that NK cells distinguish antigens, and memory NK cells
expand and protect against viral pathogens (113–115). These studjci.org   Volume 129   Number 9   September 2019
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ies provide new evidence that memory-like NK cells survive longterm and could be targeted to promote vaccine-induced protective
immunity against Mtb infection. A comprehensive evaluation of the
role of memory-like NK cell phenotype and function in household
contacts who develop active TB will improve our understanding of
the protective mechanisms against infection and subsequently facilitate development of interventions to prevent development of active
TB. Further understanding of these mechanisms will also lay the
groundwork for developing novel methods to stimulate memorylike NK cell–mediated immunity against TB.

Insights gained from BCG vaccination in human
studies

Historically, it was not known whether the benefits of BCG were
conferred predominantly through prevention of Mtb infection or
through prevention of progression to TB disease in those infected.
Autopsy data from 150 people and national tuberculin data supported the conclusion that there was no evidence to support the
suggestion that BCG vaccination can prevent the establishment of
infection in an exposed human (116). Since there was no difference
in TST positivity between BCG-vaccinated and unvaccinated individuals, but BCG vaccination was accompanied by differences in
TB pathology, it was assumed that BCG protected mainly against
progression to disease.
With the introduction of IFN-γ release assays (IGRAs), which
assess the T cell response to Mtb antigens that are not secreted by
BCG, protection against Mtb infection could be assessed without
confounding test results based on BCG itself. Soysal et al. studied more than 900 child household TB case contacts in Turkey
and found a significant reduction in ELISPOT positivity in those
who were BCG vaccinated (117). A subsequent systematic review
(118) by Roy et al. confirmed this result across 14 cross-sectional
studies, with an estimated protection against infection of 19%
(95% CI, 8%–29%). Longitudinal studies whereby an IGRA test
was repeated after about 3 months in those initially negative,
suggested that the protective effect is even greater in relation to
a specific exposure. Hill et al. showed that BCG vaccination was
associated with a 50% (95% CI, 20%–100%) reduction in the risk
of ELISPOT conversion after 3 months in Gambian contacts (119).
A remarkably similar estimate (45%; 95% CI, 24%–60%) was
obtained by Verrall et al. in Indonesian case contacts (120). Furthermore, in the Indonesian contacts, BCG protection decreased
with increasing exposure, suggesting that the immune mechanism
for protection could be overcome with increased exposure to the
pathogen. This latter finding could have implications for understanding different levels of protection from BCG across populations with varying intensity of Mtb transmission, protection being
weakest in high-TB-burden settings (121). In addition, the study by
Verrall et al. found evidence of BCG protection against infection
up until the age of 30 years, which is consistent with recent studies
suggesting that BCG protection against TB disease lasts at least 20
years when given at birth or at school age (122, 123).
A recent randomized controlled trial among adolescents
in South Africa provided further support for a protective effect
of BCG against Mtb infection. Among 990 HIV- and QFTnegative adolescents, sustained QFT conversion was 11.2% in
those who received placebo and 6.7% among those who were
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BCG revaccinated over 2 years of follow-up, representing a
45.5% reduction (5).
The mechanisms of protection against Mtb infection induced
by BCG vaccination are likely to involve innate immune mechanisms, including trained immunity. Interestingly, in the recently
published randomized trial that showed a protective effect of
BCG revaccination against Mtb infection, unrelated respiratory tract infections were also significantly less common (5, 124),
supporting a strong increase in heterologous protection against
infections, which is suggestive of trained immunity. Epidemiological reports suggest protection against nonspecific infections
by BCG for up to 4–5 years after vaccination in infants (125), and
experimental studies in humans have shown the persistence of
trained immunity for at least one year after BCG vaccination
(126). In addition, BCG-induced protection against Mtb infection was associated with higher production of proinflammatory
cytokines following heterologous stimulation with Streptococcus
pneumoniae and E. coli (120), an observation reminiscent of
trained immunity (127, 128). Thus, while murine studies suggest
that training of HSCs requires access to the BM (82), whether
intradermal BCG vaccination in humans similarly accesses
the BM is not known and will no doubt be the target of future
research. We envision that there are two major pathways that
can lead to trained immunity in HSCs during vaccination: (i) a
direct pathway, functioning via access of the vaccine (e.g., BCG)
in the BM, likely by generation of an inflammatory milieu that
leads to HSC training; and (ii) an indirect pathway, via systemic
release of exogenous (e.g., PAMPs) or endogenous mediators
(e.g., DAMPs, cytokines, colony-stimulating factors). HSCs
express receptors that are important in the activation/mobilization of HSCs (95, 129). Thus, systemic release of DAMPs as well
as cytokines (e.g., GM-CSF, IFN-γ) (81) during vaccination can
reach the BM to train HSCs. Following intradermal BCG vaccination in humans, the systemic release of PAMPs, DAMPS, and/or
cytokines is most likely responsible for training HSCs.

Harnessing innate immunity for better vaccines

The studies reviewed above provide evidence that innate immune
processes and, in particular, adjuvant activity and trained immunity, are important components of the protective effects of BCG
vaccination against TB. A detailed understanding of these processes brings hope that they can be used for the design of new and
more effective vaccines.
Which processes may be enlisted for this end? First, understanding the molecular mechanisms that mediate the biological
action of adjuvants is a step toward precise fine-tuning of the type
of T or B cell needed in an infection in general, and in TB in particular. For example, understanding the PRR and signaling pathways leading to the induction of a Th1/Th2/Th17/TFH response
will permit the design of adjuvants with specific activity toward
inducing a particular type of Th response. Second, integration of
trained innate immunity within the biological effects of future
vaccines holds promise for improved vaccine effectiveness.
Indeed, a vaccine that combines improved antimicrobial effects
of both innate (trained immunity) and adaptive (classical immune
memory) mechanisms would likely be more effective than current
vaccines. Third, these developments should improve the outcome
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of vaccination in populations at higher risk from infection, such
as the elderly. Indeed, adaptive immune responses are defective
at extreme ages, and incorporation of trained immunity into vaccines designed for use in the elderly may circumvent this problem.
In conclusion, future studies are needed to investigate the
impact of the induction of trained immunity on vaccination effects.
These studies must focus on the mechanisms involved and how to
effectively trigger them. We predict that the impact of combining
trained immunity with classical adaptive immune memory will be
fully realized in the vaccine community in the years to come. Further definition of trained immunity should enhance approaches to
our vaccine armamentarium.
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